| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 53 |
| 1 | PEMBROLIZUMAB | 48 |
| 2 | PREDNISONE | 30 |
| 3 | ESOMEPRAZOLE MAGNESIUM | 28 |
| 4 | ESOMEPRAZOLE | 18 |
| 5 | METHOTREXATE SODIUM | 18 |
| 6 | METHOTREXATE | 17 |
| 7 | OMEPRAZOLE | 16 |
| 8 | OMEPRAZOLE MAGNESIUM | 16 |
| 9 | RITUXIMAB | 15 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE | 9 | 0.0079 |
| 1 | IBALIZUMAB | 1 | 0.0019 |
| 2 | AVELUMAB | 5 | 0.0012 |
| 3 | CEMIPLIMAB-RWLC | 2 | 0.0010 |
| 4 | DANTROLENE SODIUM | 1 | 0.0009 |
| 5 | PYRIMETHAMINE | 1 | 0.0008 |
| 6 | CALCIFEDIOL | 2 | 0.0008 |
| 7 | CABAZITAXEL | 2 | 0.0006 |
| 8 | DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE | 1 | 0.0006 |
| 9 | NIVOLUMAB | 53 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 4 | 0.0058 |
| 1 | CD4-directed Blocking Antibody [EPC] | 1 | 0.0019 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 102 | 0.0010 |
| 3 | Dihydrofolate Reductase Inhibitor Antimalarial [EPC] | 1 | 0.0008 |
| 4 | CD38-directed Cytolytic Antibody [EPC] | 3 | 0.0005 |
| 5 | Programmed Death Ligand-1 Blocker [EPC] | 10 | 0.0005 |
| 6 | Calcitonin [EPC] | 1 | 0.0003 |
| 7 | CTLA-4-directed Blocking Antibody [EPC] | 12 | 0.0002 |
| 8 | Paramagnetic Contrast Agent [EPC] | 1 | 0.0002 |
| 9 | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | 4 | 0.0002 |